Asker Healthcare Group AB (ASKER) AI Stock Analysis

• Market Cap: kr32.19B
• Dividend Yield: N/A
• Average Volume (3M): 2.11M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SE
• Employees: 4,238
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.62
• Shares Outstanding: 383,036,500
• 10 Day Avg. Volume: 4,648,973
• 30 Day Avg. Volume: 2,108,945
• PEG Ratio: 1.15
• Price to Book (P/B): 9.24
• Price to Sales (P/S): 2.13
• P/FCF Ratio: 36.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr132.00
• Price Target Upside: 57.09% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 70 Neutral
• Price Target: kr144.00 ▲(71.37% Upside)

Asker Healthcare Group AB's strong financial performance and bullish technical indicators are leading factors in its stock score. However, the lack of valuation data creates uncertainty, preventing a higher score.

Asker Healthcare Group AB Business Overview & Revenue Model

Company Description

Asker Healthcare Group AB provides medical supplies, devices, and equipment, and related solutions that support patient care. It offers protective products, infusion products, and dressings; measuring instruments for diabetes and blood pressure; and endoscopy equipment, incubators, and ventilators, as well as pharmaceuticals. The company also provides, supplies, and distributes fittings and equipment; veterinary equipment; surgical and diagnostic instruments; medical supplies and equipment for urology, ultrasound diagnostics, laser treatment, and regenerative medicine; medical equipment for operating rooms, polyclinics, and day surgeries; hygiene equipment; equipment and products for beauty clinics; defibrillators and wound care products; and health-related protection and trauma products for emergency care, police service, and military. In addition, it offers develops and sells disposable medical supplies under the Evercare, Selefa, and Embra brands; distributes eye surgery products; and develops and sells products for time-management, communication, and cognition for schools, assistive technology centres, and other public services. Further, the company provides support and assistance to people needing wound, diabetes, and urological care; ostomy, urology, and rehab services; ambulance services; products for physiotherapy practices; supplies exercise and treatment equipment and measurement; and sells and rents out various mobility aids and rehab products, such as pressure-relieving mattresses and cushions, as well as manufactures and distributes pressure care products. The company operates in Sweden, Norway, Finland, Estonia, Latvia, Lithuania, Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, Czech Republic, and Poland. Asker Healthcare Group AB was founded in 2018 and is based in Danderyd, Sweden.

How the Company Makes Money

Asker Healthcare Group AB generates revenue primarily through the sale and distribution of medical devices and healthcare consumables to healthcare providers. Key revenue streams include direct sales to hospitals, clinics, and nursing homes, as well as partnerships with manufacturers to supply a broad range of healthcare products. The company's earnings are bolstered by its extensive distribution network and long-standing relationships with both healthcare providers and suppliers, enabling it to efficiently meet the demands of the healthcare industry.

Asker Healthcare Group AB Financial Statement Overview

Summary

Asker Healthcare Group AB demonstrates strong financial performance with significant revenue growth and improved operational margins. The company's cash flow is robust, supporting growth and operational needs. Moderate leverage and a stable equity base provide a solid financial foundation.

Income Statement

Asker Healthcare Group AB has demonstrated strong revenue growth, with a 11.7% increase from 2023 to 2024. The gross profit margin is solid at 39.1%, and there is significant improvement in the EBIT margin to 6.4% from 4.3% in the previous year, indicating enhanced operational efficiency. The EBITDA margin also improved to 9.8%. However, the net profit margin is relatively low at 2.4%, reflecting potential non-operational costs or tax impacts.

Balance Sheet

The company's debt-to-equity ratio is 1.72, indicating moderate leverage but a slight increase in debt levels. The equity ratio of 26.4% suggests a balanced asset structure, though with room for improvement. Return on equity stands at 10.4%, which is reasonable but could be enhanced for better shareholder returns.

Cash Flow

Operating cash flow to net income ratio is robust at 3.41, suggesting strong cash generation relative to profits. There is a slight decline in free cash flow from 2023 to 2024, but the free cash flow to net income ratio remains favorable at 2.44. The overall cash flow generation is positive, supporting growth and operational needs effectively.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.98B	15.03B	13.45B	11.72B	9.35B
Gross Profit	3.26B	5.88B	4.52B	3.78B	2.61B
EBITDA	654.00M	1.47B	1.12B	1.12B	670.00M
Net Income	220.00M	360.00M	203.00M	430.00M	467.00M
Balance Sheet
Total Assets	15.21B	13.12B	11.33B	10.23B	7.36B
Cash, Cash Equivalents and Short-Term Investments	1.32B	490.00M	391.00M	211.00M	494.00M
Total Debt	5.11B	5.96B	4.97B	4.74B	3.93B
Total Liabilities	8.78B	9.62B	8.29B	7.44B	5.54B
Stockholders Equity	6.39B	3.47B	3.02B	2.76B	1.79B
Cash Flow
Free Cash Flow	42.00M	879.00M	901.00M	853.00M	258.00M
Operating Cash Flow	320.00M	1.23B	1.05B	976.00M	382.00M
Investing Cash Flow	-1.27B	-1.46B	-783.00M	-1.86B	-843.00M
Financing Cash Flow	1.81B	305.00M	-83.00M	572.00M	619.00M

Asker Healthcare Group AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BONEX	73 Outperform	kr19.86B	134.17	20.14%	―	44.52%	-49.29%
ASKER	70 Neutral	kr32.19B	―	―	―	―	―
ALIF.B	60 Neutral	$21.83B	64.73	6.27%	0.42%	4.56%	185.59%
MCOV.B	59 Neutral	kr38.50B	79.29	―	0.57%	15.92%	82.51%
VITR	57 Neutral	kr18.57B	40.80	3.46%	0.80%	0.14%	―
VIMIAN	57 Neutral	€15.04B	58.58	3.34%	―	15.07%	117.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Asker Healthcare Group AB Corporate Events

Asker Healthcare Group Expands into French Market with Finmed Acquisition

Asker Healthcare Group has announced its acquisition of 80% of Finmed SAS, a leading provider of medical devices and solutions in France. This strategic move marks Asker’s first acquisition in France, aiming to strengthen its presence in the large French healthcare market. The acquisition, which is pending regulatory approval, is expected to close in the fourth quarter of 2025 and positively impact the group’s EBITA margin.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK100.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Announces Extraordinary General Meeting

Asker Healthcare Group AB has announced an Extraordinary General Meeting scheduled for August 27, 2025, in Stockholm. The meeting will address shareholder participation, either in person or through advance voting, with specific instructions provided for both methods. This meeting is significant for stakeholders as it involves decision-making processes that could impact the company’s governance and strategic direction.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK100.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Achieves Growth Through Strategic Acquisitions in Q2 2025

Asker Healthcare Group reported a 9% increase in net sales for Q2 2025, driven by organic growth and strategic acquisitions, despite negative exchange rate impacts. The company signed four acquisition agreements in the quarter, enhancing its market presence and product offerings, and maintained stable operational performance, aiming for continued growth in the fragmented European medtech market.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK100.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Expands with Acquisition of Dartin

Asker Healthcare Group has announced the acquisition of Dartin, a niche distributor of medical equipment in the Czech Republic and Slovakia. This strategic move aims to enhance Asker’s offerings in the intensive care and elderly care segments, with Dartin’s specialization in neonatal care and patient lifting devices. The acquisition is expected to positively impact Asker’s EBITA margin and will be finalized in the third quarter, strengthening the group’s position in the European healthcare market.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK100.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Schedules Q2 2025 Financial Webcast

Asker Healthcare Group announced it will release its interim report for January-June 2025 on July 22, followed by a webcast presentation featuring CEO Johan Falk and CFO Thomas Moss. This event allows investors, analysts, and media to engage with the company’s leadership, providing insights into Asker’s financial performance and strategic direction.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK100.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Acquires Scan Modul to Enhance Hospital Logistics Solutions

Asker Healthcare Group has announced its acquisition of Scan Modul International Holding B.V., a leading provider of hospital workflow solutions based in the Netherlands. This acquisition is expected to enhance Asker’s existing offerings by integrating Scan Modul’s modular storage solutions, which facilitate efficient hospital logistics. The acquisition is anticipated to positively impact Asker’s EBITA margin and will be finalized on July 3, 2025.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK100.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Acquires Danish Medical Supplier Kirstine Hardam

Asker Healthcare Group has announced the acquisition of Kirstine Hardam A/S, a prominent distributor of medical supplies in Denmark, which will enhance Asker’s presence in the Danish market. This strategic acquisition, subject to regulatory approvals and expected to close in the fourth quarter of 2025, aims to integrate Hardam’s expertise in ostomy, wound care, nutrition, and incontinence care into Asker’s portfolio, potentially strengthening its market position and operational capabilities.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK100.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Expands with Acquisition of Estonian Company ITAK

Asker Healthcare Group has announced the acquisition of ITAK OÜ, a leading provider of mobility and personal assistive equipment in Estonia. This strategic move aims to enhance Asker’s presence in the European healthcare market, particularly in the area of home care for an aging population. ITAK, which operates 22 service centers in Estonia and has a strong market position, will bolster Asker’s offerings and support its growth strategy. The acquisition is pending regulatory approval and is expected to close in the third quarter of 2025.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK100.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.

Asker Healthcare Group Reports Strong Q1 2025 Growth and Strategic Acquisitions

Asker Healthcare Group AB reported a strong first quarter in 2025, with a 16% increase in net sales and a 17% rise in adjusted EBITA, driven by both organic growth and strategic acquisitions. The company’s recent listing on Nasdaq Stockholm and acquisitions in Ireland, the UK, and the Netherlands are expected to enhance its market position and support its goal of becoming a leading medtech provider in Europe.

The most recent analyst rating on (SE:ASKER) stock is a Buy with a SEK100.00 price target. To see the full list of analyst forecasts on Asker Healthcare Group AB stock, see the SE:ASKER Stock Forecast page.